AzurRx (AZRX) Corporate Media Kit

5 Recent Developments Financial (July 2020) • Raised gross proceeds of $15.2 MM in private placement of Series B Preferred Stock ($13.5 MM net proceeds) • Exchanged $6.9 MM principal of convertible notes into Series B Preferred Stock • Sufficient capital to fund Phase 2 programs and Phase 3 preparations for MS1819 • Clean balance sheet – no debt Clinical • Monotherapy o Phase 2b OPTION 2 clinical trial initiated (July 2020) o First 3 patients dosed and 9 clinical trial sites activated (August 2020) • Combination Therapy o Interim data on first 5 patients (25% of study) released (August 2020) o Primary and secondary efficacy endpoints met with no safety issues